Grand Challenges Canada awards $100,000 grants to innovators worldwide for bold ideas to tackle health problems in resource-poor countries. Researchers are developing new technologies, such as a high-tech wristband to monitor pregnant women's vital signs and a trading system that rewards vaccination with farm inputs.
Researchers identified trust as a crucial factor in the success or failure of agbiotech public-private partnerships. The study found that integrity, open communication, and accountability were essential components of trust in these partnerships, while a lack of transparency and poor performance can erode trust.
The Saving Brains initiative aims to improve conditions for children's development, with funding focused on malnutrition, maternal depression, premature birth, and malaria. Innovations include Kangaroo Mother Care, Vitamin A supplementation, and early treatment of malaria to prevent brain injury.
Researchers develop affordable, easy-to-use devices for rapid disease diagnosis in rural communities. Innovative projects include a handheld analyser capable of identifying malaria from DNA fingerprint and a piece of woven fabric that tests blood or urine for disease.
Studies detail the successes of African entrepreneurs creating affordable technologies to address local diseases. Despite challenges, some organizations have cleared major hurdles to finance and commercialize their products, offering hope for improved health in sub-Saharan Africa.
Experts warn that biotech companies in emerging economies are making innovative contributions to address health problems. They have brought affordable products to prevent, diagnose and remedy illnesses of local concern, but risk diverting focus from diseases of poverty as they grow in financial strength.
A study found that south-south collaborations between biotech firms in developing countries are increasing, enabling the production of affordable health products. These collaborations have already led to successful vaccine development and distribution, such as the Brazil-Cuba collaboration during Africa's meningitis outbreak.
The eradication of smallpox achieved significant public good with lives saved and prevented. Similarly, completing polio eradication is justified by moral obligations to prevent harm and protect future generations. The authors argue that finishing the job is an ethical imperative due to the capacity and opportunity to do so.
Chinese researchers have become a leading contributor to peer-reviewed scientific literature on clock-reversing regenerative medicine, with over 1,100 publications in 2008. New regulations aim to improve patient safety and restore China's global reputation.
Researchers identified 78 homegrown health biotechnology companies producing innovative products for all neglected diseases, including the Big 3. A proposed 'Global Health Accellerator' service aims to connect these firms with expertise and funding to reach additional villages worldwide.
A new study found that Canadian health biotech firms collaborating with developing countries have a strong interest in building partnerships, driven by access to emerging markets and cost savings. Joint R&D activities are nearly as common as distribution arrangements, reflecting bi-directional knowledge-intensive collaboration.
Researchers have discovered biomarkers in blood that could aid diagnosis of severe and debilitating forms of malaria, including placental and cerebral malaria. Elevated levels of C5a and angiopoietin-2 were found to be associated with these forms of the disease, potentially allowing for earlier detection and targeted treatment strategies.
Four developing countries are leading the way in establishing domestic capacity for genomic medicine, improving national health, reducing medical costs and bolstering economies. Mexico's program is the most comprehensive, with genotyped over 1,200 people to study genetic relationships with various health problems.
Brazil is transitioning from imitator to innovator in health-related products, with several small and medium-sized enterprises succeeding in developing innovative products. Despite facing challenges such as regulatory barriers and limited access to private equity, Brazil's biotech industry has the scientific capacity to become a major ...
China's health biotech industry boasts daring medical science innovation and stunning breakthroughs, including the world's first commercialized gene therapy product. However, firms face an uphill battle in attracting high-risk venture capital needed for innovative projects due to uncertain financial systems and export restrictions.
Researchers have created a global consensus on the 20 foremost measures needed to curb humanity's most fatal diseases. The list of Grand Challenges includes prioritizing resource allocation within health systems and mitigating the impact of poverty and urbanization.
A pioneering study has identified 13 key areas of concern for major science programs in developing countries, including community engagement, cultural acceptability, and corruption. The study aims to promote effective project planning and minimize adverse impacts on research participants.
The Indian biotech sector is poised to revolutionize the industry with its innovative products, strategies, and manufacturing capabilities. The sector has already made significant impacts on drug prices, reducing costs by up to 90% for some generic biopharmaceuticals.